SCHEMBL2882671

SCHEMBL2882671

Nc1ccc(Nc2ccnc3[nH]ccc23)c(F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 2/20 0.45
ACVR1 Q04771 2/20 0.45
BMPR1A P36894 1/20 0.45
ACVR1B P36896 1/20 0.45
ACVRL1 P37023 1/20 0.45
ROCK1 Q13464 3/20 0.45
NUDT1 P36639 1/20 0.43
TNNI3K Q59H18 1/20 0.42
ROCK2 O75116 6/20 0.41
PRKCI P41743 3/20 0.41
AXL P30530 1/20 0.41
SYK P43405 1/20 0.40
RAF1 P04049 1/20 0.38
BRAF P15056 1/20 0.38
CDK8 P49336 2/20 0.38
CCNC P24863 1/20 0.38
PLK4 O00444 1/20 0.38
PDPK1 O15530 1/20 0.38
RPS6KA5 O75582 1/20 0.38
PRKD3 O94806 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2888202 0.84 ROCK1 (0.46) TGFBR1ACVR1BMPR1AACVR1BACVRL1
SCHEMBL2887878 0.84 PRKCI (0.53) TGFBR1ACVR1BMPR1AACVR1BACVRL1
SCHEMBL13354262 0.81 TGFBR1 (0.43) TGFBR1ACVR1BMPR1AACVR1BACVRL1
SCHEMBL4404315 0.80 AURKA (0.37) ROCK1TNNI3KROCK2AXLRAF1
SCHEMBL8271232 0.80 ROCK2 (0.67) TGFBR1ACVR1BMPR1AACVR1BACVRL1
SCHEMBL2886078 0.78 TTBK1 (0.43) TGFBR1ACVR1BMPR1AACVR1BACVRL1
SCHEMBL2881534 0.78 TTBK1 (0.54) ROCK1TNNI3KPRKCIAXLAURKB
SCHEMBL2886243 0.78 TGFBR1 (0.42) TGFBR1ACVR1BMPR1AACVR1BACVRL1
SCHEMBL2882673 0.77 ROCK2 (0.50) TGFBR1ACVR1BMPR1AACVR1BACVRL1
SCHEMBL2881832 0.76 ROCK2 (0.69) TGFBR1ACVR1BMPR1AACVR1BACVRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 TGFBR1 4251/4885ACVR1 4226/4885BMPR1A 4355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.